News Business International Research
Filament Health ships botanical psilocybin to four countries for clinical investigation

(CNW) Vancouver — Filament Health Corp., a clinical‐stage natural psychedelic drug development company, announced that since March 1, 2024 it has shipped its botanical psilocybin drug candidate, PEX010, to four countries for clinical trials at leading research institutions. PEX010 will be studied in Canada, the United States, Belgium, and Israel, for a range of mental health indications such as cannabis use disorder, depression, anxiety, and alcohol use disorder.

“Filament Health is one of the largest – if not the largest – supplier of psilocybin globally,” said CEO, Benjamin Lightburn. “We are incredibly proud to facilitate potentially life-saving research around the world with our consistent production of standardized, GMP botanical psilocybin.”

Filament has completed shipments of PEX010 to Johns Hopkins University for a clinical trial studying cannabis use disorder and to Dana-Farber Cancer Institute for a trial studying the treatment of pain in cancer patients. In Belgium, Filament has supplied PEX010 to Ghent University which will examine its effects for the treatment of anxiety and mood disorder, and to Brugmann University Hospital which will study PEX010 for alcohol use disorder. In Canada, University Health Network plans to begin a Phase II clinical trial studying PEX010 for treatment-resistant depression, and the University of Calgary will study PEX010 for alcohol use disorder. In Israel, Jerusalem Center for Mental Health will investigate Filament’s drug candidate for depression and anxiety in terminal illnesses.

“Successfully navigating such a broad range of regulatory bodies is a significant achievement for Filament,” said COO, Lisa Ranken. “I am particularly proud of our team’s agility with the European Medicines Agency’s new Clinical Trials Information System.”

PEX010 is currently authorized for investigation in 30 clinical trials worldwide for 13 indications.